MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, near Madison, WI. This new $65 million, 70,000 square foot facility brings 50 new jobs to the area.

“There is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the trend towards more targeted therapeutics. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight,” said Dirk Lange, head of life science services, life science business sector of Merck KGaA. “Increasing capacity at our state-of-the-art facility in Verona, WI, will allow us to meet the need for these key cancer treatment components.”

Cancer is the second leading cause of death worldwide. HPAPIs are a critical element of targeted therapies due to their effective cell-killing abilities at low doses, resulting in reduced side effects for patients. They are used in novel cancer therapies, including antibody drug conjugates (ADCs), which are changing the landscape of cancer treatments.

MilliporeSigma has been developing multi-step, complex, and highly potent compounds for more than 30 years and continues to be an industry leader in the development and custom manufacture of these components. HPAPIs require specialized handling and manufacturing facilities that protect the safety of employees and their environment. Many potential life-saving treatments never make it to market in part due to the specialized handling requirements.

MilliporeSigma’s Verona, WI, site was the second facility in the world to be SafeBridge-certified and the company continues to meet these rigorous safety and containment requirements necessary to this day. This expansion positions MilliporeSigma as one of the largest single-digit nanogram occupational exposure limit (OEL) CDMO providers in the world. HPAPIs are measured with the most potent registering less than 10 nanograms per cubic meter. Single digit nanogram HPAPIs require highly specialized handling, which is reflected by the OEL designation.

In addition to HPAPI production, MilliporeSigma also has extensive experience developing and manufacturing ADCs. Being the first CDMO to manufacture commercially approved ADC drugs in North America, the company recently launched new technologies to advance ADC therapies. Its ChetoSensar technology gives new promise to ADCs by alleviating solubility challenges, and the new DOLCORE platform significantly reduces development and manufacturing time required, increasing speed-to-market by up to a year, ultimately getting needed therapies to patients quicker.

With more than 30 years of CDMO experience in the development and manufacturing of HPAPIs, linkers and mAbs, MilliporeSigma offers significant expertise in both clinical and commercial manufacturing. The company also has extensive CDMO experience in viral vector, lipids, LNP and mRNA manufacturing—from pre-clinical to commercial—helping to streamline steps of drug development and production with a single, highly experienced partner. Additionally, BioReliance contract testing services are integrated into the overall services offering to further streamline the development path.